Healthcare benefits strategy is being reshaped by two converging forces: accelerating cost pressure and changing purchasing behavior. Pharmacy trend continues to outpace medical, GLP-1 demand is testing long-standing budget assumptions, and chronic disease remains the primary driver of long-term healthcare spend.
At the same time, members are gaining access to care through channels that sit outside traditional benefit design, from direct-to-consumer pricing to employer-sponsored hybrid models. The result is a more complex and less centralized purchasing environment.
For benefits leaders, this is not a matter of adding new programs. In many organizations, digital health proliferation has already led to vendor fragmentation, engagement fatigue, and reporting complexity. This is fundamentally a capital allocation challenge. How should high-cost therapies be structured for long-term sustainability? Where can prevention meaningfully reduce downstream risk? How do you simplify a fragmented ecosystem while meeting growing expectations for retail-like access and transparency? The answers to these questions are redefining how leading employers and health plans approach population health strategy.
The trends that follow are not isolated developments. They are interconnected responses to this broader shift, each reflecting a growing emphasis on financial discipline, population-wide impact, and simplification within an increasingly complex healthcare landscape.
1. The Desire for More Sustainable GLP-1 Strategies
Demand for GLP-1s has only grown since they were approved for weight loss, yet cost remains a significant barrier for employers and health plans. They are grappling with difficult questions around eligibility, cost-sharing, and long-term sustainability. There is increasing recognition that medication alone is not a viable strategy. GLP-1s are most effective in helping individuals achieve long-term success when paired with a behavior change program that incorporates nutritional support and lifestyle counseling.1
Flexible access pathways through employer-subsidized or self-pay models are becoming part of the conversation as organizations seek ways to balance demand with fiscal responsibility. Solutions, like Noom Clinical, that offer flexible and affordable options for GLP-1 access, help employers and payers expand eligibility while managing costs.
Noom’s embedded GLP-1 Companion further strengthens this approach by delivering psychology-based behavior change support and resources designed to reduce side effects, preserve lean muscle, and enhance outcomes, ultimately driving greater value from medication investment.
GLP-1s will remain a core element of obesity care strategies. The differentiator will be how effectively they are integrated into broader population health frameworks.
2. The Consumerization and Disintermediation of Healthcare Purchasing
Healthcare purchasing is no longer confined to traditional benefit design. Over the past several years, manufacturers, digital health companies, and provider groups have expanded direct-to-employer and direct-to-consumer pathways. GLP-1 access models have accelerated this shift, but it extends well beyond weight management. Members are increasingly aware of cash-pay pricing, subscription models, and virtual-first care options that sit outside the traditional plan structure.
For employers and health plans, this creates a structural change in how influence and access are managed. Historically, network design and formulary controls concentrated purchasing power within the benefit. Today, members have more visibility into alternatives and are more willing to seek care outside traditional channels if cost, access, or convenience fall short. That reality cannot be ignored.
This shift introduces both complexity and opportunity. When care happens outside the core benefit, data fragmentation and safety oversight become concerns. At the same time, alternative pricing models and hybrid employer-subsidized pathways can offer flexibility in managing demand, particularly for high-cost categories such as obesity care. In some cases, structured cash-pay or co-funded models may relieve pressure on core medical and pharmacy budgets while still supporting member access.
As purchasing channels diversify, benefits leaders must think beyond binary coverage decisions. The question is no longer simply whether to cover a solution, but how to design access in a way that aligns member behavior, cost exposure, and clinical outcomes. Organizations that partner with platforms capable of operating across employer-sponsored and direct-to-consumer pathways will be better positioned to adapt to this evolving landscape.
Consumer expectations are increasingly influencing healthcare design and purchasing decisions. Benefits strategies that account for this reality, rather than resist it, will have greater flexibility in managing cost, engagement, and long-term risk.
3. Vendor Consolidation and the Push for Integrated Platforms
Over the past decade, the digital health market has exploded with point solutions targeting individual conditions or narrow use cases. While many of these tools offer clinical value, they have also created administrative complexity. Employers often manage dozens of vendor relationships, multiple data streams, overlapping engagement campaigns, and inconsistent reporting frameworks.
Benefits leaders are increasingly prioritizing consolidation. They are seeking platforms that can address multiple conditions, engage broad populations, and demonstrate measurable outcomes within a unified experience.
Engagement is becoming a central metric in vendor evaluation. Clinical efficacy matters, but without sustained member participation, even the best-designed programs underperform financially. Vendors that can drive consistent engagement across large populations will emerge as a frontrunner.
Integrated cardiometabolic platforms, like Noom Health, can reduce vendor fatigue by addressing weight, diabetes, and associated risks through behavioral change within a single ecosystem. When paired with strong engagement metrics, these solutions are more likely to meet the demands of cost-conscious decision-makers.
4. The Shift from Condition-Specific Programs to Metabolic Health Models
There is increasing recognition that many of the most prevalent and costly chronic conditions share common underlying drivers — poor nutrition, sedentary behavior, inadequate sleep, chronic stress, and other modifiable risk factors.2 As a result, employers and payers are increasingly viewing population health through a broader lens: metabolic health. Rather than investing in siloed programs that target an individual after a specific diagnosis, metabolic health-focused benefits can reduce the risk for multiple chronic conditions simultaneously.
Consider that metabolic dysfunction makes an individual:3
- 5 times more likely to have type 2 diabetes
- 2 times more likely to have heart disease
- Up to 4 times more likely to have a stroke or heart attack
An approach centered on improving overall metabolic health can influence outcomes across weight management, obesity care, diabetes, and more, creating multiplier effects across a population. In fact, McKinsey Health Institute estimates that taking a broad approach to metabolic health is three to four times more impactful than focusing on weight loss alone and could lead to a $5.65 trillion annual GDP uplift by 2050.4
This reframe marks a shift in benefits strategy away from managing downstream symptoms of chronic disease to addressing upstream risk.
For benefits leaders, the implication is significant: targeting root causes at scale may generate greater long-term financial impact than treating conditions one at a time. Integrated metabolic solutions that support sustainable behavior change are emerging as a more strategic investment than isolated, reactive interventions.
5. Personalization at Population Scale
Benefits leaders face a competing mandate: reach the entire population while also delivering individualized experiences that drive meaningful outcomes. Historically, personalization and scale were at odds. High-touch interventions were expensive. Scalable solutions were too generic. Advancements in AI, adaptive coaching models, and real-time data integration are changing that equation.
Personalization is evolving beyond demographic targeting to incorporate behavioral signals, motivation levels, readiness for change, and even real-time biometric inputs from wearables and connected devices.5 Programs can now adapt dynamically, adjusting recommendations as individuals progress, plateau, or disengage. This matters financially because personalization drives higher engagement, which leads to better outcomes — increasing the value of each dollar spent. For example, predictive capabilities such as Noom’s glucose forecasting tool can help individuals anticipate how certain foods may impact blood sugar and offer proactive recommendations to avoid a spike. When individuals see direct connections between daily choices and measurable health outcomes, engagement deepens.
The future of benefits is not a tradeoff between one-size-fits-all or high-cost customization. It’s intelligent personalization delivered at scale.
6. Prevention as a Cost-Containment Strategy — Not a Perk
Prevention has traditionally been framed as a wellness initiative. It’s valuable, but secondary to core medical benefits focused on chronic disease management. That framing is beginning to shift. In 2023, more than three-quarters (76.4%) of US adults reported having one or more chronic conditions with obesity, hypertension, and diabetes being the most prevalent.6 7According to the World Health Organization, these conditions are considered “largely preventable and manageable through preventive interventions across the lifecycle.”8
With chronic disease accounting for the majority of healthcare spend, prevention is increasingly viewed as a financial imperative. Waiting until someone crosses a diagnostic threshold into a high-risk category is costly. Disease progression may trigger a domino effect, influencing pharmacy costs, acute care events, and long-term claims escalation. That’s why prevention is crucial.9 Scalable population health strategies that proactively intervene early can engage people across the risk spectrum, addressing issues before they meet the threshold for disease.
Additionally, it’s not just high-risk individuals who are targeted, but entire employer and payer populations which can deliver stronger ROI. This is especially true of programs like Noom that address lifestyle change, helping people to build the healthy habits that are the foundation for lasting health. Prevention is no longer a “nice-to-have.” It is increasingly a lever for long-term cost stability.
The Path Forward
Together, these five market shifts point toward a broader transformation in health benefits design. The future is less about layering new point solutions onto an already crowded ecosystem and more about building a cohesive, prevention-first benefits strategy. Organizations that embrace this model are not simply reacting to healthcare trends. They are redesigning benefits around long-term population health and financial resilience.
Footnotes
- https://now.tufts.edu/2025/06/04/long-term-success-glp-1s-hinges-more-just-prescription ↩︎
- https://doi.org/10.3390/healthcare12242520 ↩︎
- https://www.ummhealth.org/health-library/metabolic-syndrome-your-risk-for-chronic-disease
↩︎ - https://www.mckinsey.com/mhi/our-insights/the-path-toward-a-metabolic-health-revolution ↩︎
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10084530/ ↩︎
- https://www.healthsystemtracker.org/chart-collection/how-has-the-burden-of-chronic-diseases-in-the-u-s-and-peer-nations-changed-over-time/
↩︎ - https://pmc.ncbi.nlm.nih.gov/articles/PMC12007472/ ↩︎
- https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight ↩︎
- https://www.omicsonline.org/open-access-pdfs/the-role-of-preventive-care-in-reducing-healthcare-costs-a-public-health-perspective.pdf ↩︎
